Aptahem

The article, titled "Antithrombotic but not anticoagulant activity of the thrombin-binding RNA aptamer Apta-1", has been accepted for publication in BJP and summarizes several years of research by Aptahem, as well as recent collaborative efforts with Örebro University. The article details a thorough and comprehensive evaluation of Apta-1's unique properties, which required time and precision due to the compound's remarkable complexity. What makes this discovery so remarkable is Apta-1's ability to not only combat life-threatening thrombosis but also acute inflammatory conditions, without affecting normal blood coagulation. This paves the way for future breakthroughs and additional studies.

Dr. Luiza Jedlina, CSO, commented: "I am very happy that we can finally reveal the confirmed complexity of Apta-1 after I first recognized the amazing potential of this drug candidate, which led to the founding of Aptahem. I am absolutely thrilled that the results of our groundbreaking research have come together through our collaboration with Örebro and found recognition and validation by BJP."

Mikael Lindstam, CEO, added: "These validated results, which have the potential to revolutionize the treatment of serious inflammatory diseases, represent a great success for Aptahem and open the door for further studies and attention. Over the years, new findings have continuously opened up new questions about the mechanisms involved, which required investigation. Now, through our collaboration with Örebro University, we can conclude that an enormous amount of work has resulted in understandings that are vital for progress, especially in regard to potential partners."

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.